Polycystic Ovary Syndrome, a modern epidemic: An overview by Mohd, Maqsood et al.
 Mohd et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2019; 9(3):641-644 
ISSN: 2250-1177                                                                                    [641]                                                                                    CODEN (USA): JDDTAO 
Available online on 15.05.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                               Review Article 
Polycystic Ovary Syndrome, a modern epidemic: An overview 
Maqsood Mohd*, Mudasir Maqbool, Mohmad Amin Dar, Insha Mushtaq 
Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar-190006, Jammu and Kashmir, India 
 
ABSTRACT 
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting women, but can be very difficult to diagnose and treat due to 
vague presentation of symptoms and a lack of standardization in treatment. PCOS is characterized by hyperandrogenic manifesta tion like acne, 
hirsutism and chronic anovulation and is associated with metabolic derangement such as hyperlipidemia, hyperinsulinemia, insulin resistance 
and Type 2 diabetes mellitus.The cause of polycystic ovary syndrome is still unclear due to its multifactorial complexity; however, it has been 
observed and understood that there are several environmental and genetic factors, such as genetic variations like mutations and 
polymorphisms, differential regulation of genes, and pathways, may contribute to the pathogenesis of PCOS.The occurrence of considerable 
heterogeneity in clinical symptoms and endocrine features associated with PCOS implies that some women with Polycystic Ovaries on 
ultrasound scan may even exhibit none of the other features of PCOS.There is a spectacular increase in the prevalence of PCOS all over the 
world especially in Asia. The condition seems to be on a rise in Kashmir valley although systematic studies on the subject are still underway. In 
this review article, we will briefly provide an overview about the polycystic ovary syndrome.  
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Introduction 
Polycystic ovary syndrome (PCOS) is an exceedingly 
prevalent metabolic disorder and possibly constitutes the 
most frequently encountered endocrinopathy to affect 
women. There is considerable heterogeneity of symptoms 
and signs among women with PCOS, and for an individual 
these may change over time. The extreme end of the 
spectrum, once known as Stein-Leventhal syndrome, 
encompasses the combination of hyperandrogenism 
(hirsutism, acne, alopecia and elevated serum testosterone 
concentrations), severe menstrual disturbance (amenorrhea 
or oligomenorrhea) and obesity1.The prevalence rate of 
PCOS appears to be higher in countries where obesity and 
type 2 diabetes are common2. Not all PCOS women are obese 
and hence they vary in degrees of thinness to fatness, 30-
75% of PCOS cases contend with being overweight or obese3. 
Within the past two decades, the developing nations as India 
and China2 began relying on Westernized diets and lifestyle. 
It is predicted that there may be up to a six fold increase in 
obesity prevalence in the next ten years especially for India 
who already has the highest rates of diabetes in the 
world4.Most of the symptoms associated with PCOS appear 
to be linked with either high androgen or insulin hormone 
levels 5, 6. The clinical presentation and expression of PCOS 
symptoms viz. polycystic ovaries, high levels of androgens 
and irregular periods are variable from patient to patient. It 
is a fact that not all women with polycystic ovaries have 
PCOS and not all women with PCOS have polycystic ovaries. 
The symptoms may vary from mild to more severe, and some 
women may only have a few symptoms, while others have 
more. This complexity has made it very difficult for clinicians 
to find a clear cut way to diagnosis a patient with PCOS and 
to account for exact prevalence rates 7, 8. 
Clinical Presentation of PCOS 
The clinical presentation of PCOS differs widely. Women with 
PCOS often seek curative treatment for menstrual 
disturbances, hyperandrogenism (clinical features), and 
infertility. Menstrual irregularities commonly observed in 
PCOS are oligomenorrhea, amenorrhea, and prolonged 
erratic menstrual bleeding 9. However, 30% of women with 
PCOS will have normal menses10. Approximately 85%–90% 
of women with oligomenorrhea have PCOS while 30%–40% 
of women with amenorrhea will have PCOS 11. Hirsutism is a 
common clinical presentation of hyperandrogenism 
occurring in up to 70% of women with PCOS 12. It is 
evaluated using a modified Ferriman–Gallwey scoring 
system (mFG score) 13. This tool is used to evaluate hair 
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growth at nine body sites: upper lip, chin, chest, upper 
abdomen, lower abdomen, upper arms, upper back, lower 
back and thighs 14. Over 90% of normally menstruating 
women with hirsutism are identified through ultrasound to 
have polycystic ovaries (PCO)15. In addition, PCOS occurs in 
50% of women with less severe distribution of unwanted 
hair growth 16. Acne is also a manifestation of 
hyperandrogenism but is less prevalent in PCOS and less 
specific than hirsutism. Approximately 15%–30% of adult 
women with PCOS present with acne 17, 18.  The variations in 
prevalence of hirsutism and acne may be related to the 
difference in expression of 5α-reductase in the sebaceous 
gland and the hair follicle, and resulting in higher 
dihydrotestosterone in the hair follicle 19. Out of these 
women presenting with severe acne, over 40% were 
diagnosed with PCOS 20. Some experts suggest that women 
presenting with acne be asked about their menstrual history 
and be evaluated for other signs of hyperandrogenism21. 
Infertility affects 40% of women with PCOS 22. PCOS is the 
most prevalent reason for an ovulatory infertility. 
Approximately 90%–95% of an ovulatory women attending 
infertility clinics have PCOS.  PCOS women have a normal 
number of primordial follicles where as primary and 
secondary follicles are significantly increased. However, due 
to disorders in factors involved in normal follicular 
development, the follicular growth becomes arrested as 
follicles reach a diameter of 4–8 mm. As a result dominant 
follicle does not develop, ovulation does not ensue 22, 23. In 
addition, spontaneous abortion occurs more frequently in 
PCOS with incidences ranging from 42%–73% 24, 25. 
Molecular alterations in PCOS 
The exact cause of polycystic ovary syndrome is still 
unknown due to its multifactorial complexity; however, it 
has been observed and understood that there are several 
environmental and genetic factors, like genetic variations 
like mutations and polymorphisms, differential regulation of 
genes, and pathways, may contribute to the pathogenesis of 
PCOS 26-28. Various studies elaborate, association of 
differential regulation of genes at various levels , which 
includes, genes that are increasingly regulated and decreased 
in PCOS and the associated effects of differential regulation 
of genes were studied 29. The detailed literature study 
revealed that the differential expression of genes involved in 
various biological process such as androgen biosynthesis, 
angiogenesis, follicular development, and at different stages 
of the embryonic development, contributes to the several 
changes of the gene regulation at the molecular level 30, 
including the differential regulation of genes and mRNAs in 
the PCOS and its serious effects, including endometrial 
receptivity, implantation failure, early pregnancy loss, PTB, 
insulin resistance, hyperandrogenesim in women with PCOS 
31, 32. On the note of mutations and polymorphisms, it’s been 
studied that the genetic variations play an important role in 
the pathogenesis of PCOS across various populations or 
ethnicities. Although several studies have been performed 
and several hundreds of articles are published in the public 
domain on PCOS, the information is highly scattered or 
dispersed in the literature, which is the most specific 
challenge for researchers. Hence, the need to have a 
comprehensive coverage of scientific, evidence-based 
information on PCOS-associated genes and its molecular 
mechanism becomes essential and critical 33.The detailed 
literature study revealed several genes and the genetic 
variations in PCOS and its critical effects, such as ovary 
failure 34, obesity 35, spontaneous abortion36, recurrent 
pregnancy loss 37etc. The causal genetic variants were 
grouped at various levels, including mutation, single 
nucleotide polymorphism, etc., and the associated 
phenotypic effects of those variations or alterations were 
captured. Despite a number of candidate genes being 
identified, a primary pathological cause of PCOS has still not 
been identified. 
Diagnosis of PCOS   
Three main diagnostic criteria employed for diagnosis of 
PCOS are as follows;   
A. The National Institute of Health/National Institute of Child 
Health and Human Development consensus conference 
criteria is the most commonly employed diagnosis for the 
PCOS and is as follows38 ;  
1. Clinical and/or biochemical hyperandrogenism. 
2. Oligo-anovulution (oligomenorrhea/amenorrhea)  
Exclusion of disorders like non-classical congential adrenal 
hyperplasia (NCAH), hyperprolactinemia, androgen 
producing tumors, thyroid dysfunction and cushing 
syndromes.   
B. ROTTERDAM CRITERIA 2003 39 
The Rotterdam criteria for the diagnosis of PCOS (2003) 
states 2 of the 3 features need to be present to make the 
diagnosis and with the exclusion of other etiologies (like 
congenital adrenal hyperplasia, Cushing’s syndrome, 
androgen-secreting tumors). These features include;  
 (1) Oligo- or anovulation. 
(2) Clinical / biochemical signs of hyperandrogenism and 
(3) PCO (either 12 or more follicles measuring 2–9 mm in 
diameter, or an ovarian volume of >10 cc).    
C. ANDROGEN EXCESS SOCIETY (AES) 40 
Diagnostic criteria laid down by include hyperandrogenemia 
and or hyperandrogenism plus one out of 2 remaining 
criteria of oligo/amenorrhea and polycystic ovaries on 
ultrasonography. 
Treatment Guidelines and Recommendations for 
PCOS41, 42 
Endocrine Society Clinical Practice Guideline (Ligro et al, 
2015) for treatment of polycystic ovaries recommends:  
1. HCs (ie, oral contraceptives, patches, or vaginal rings) 
as the first-line management for the menstrual 
abnormalities and hirsutism/acne of PCOS.  
2. Use of exercise therapy in the management of 
overweight and obesity in PCOS. Weight loss strategies 
should begin with calorie-restricted diets (with no 
evidence that one type of diet is superior) for 
adolescents and women with PCOS who are overweight 
or obese.  
3. Suggest against the use of Metformin as a first line 
treatment of cutaneous manifestations, for prevention 
of pregnancy complications, or for the treatment of 
obesity.   
4. Recommend metformin in women with PCOS who have 
T2DM or IGT who fail lifestyle modification. For women 
with PCOS with menstrual irregularity who cannot take 
or do not tolerate HCs, suggest metformin as second-
line therapy.   
5. Recommend Clomiphene citrate (or comparable 
estrogen modulators such as letrozole) as the first-line 
treatment of anovulatory infertility in women with 
PCOS.  
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6. Suggest the use of Metformin as an adjuvant therapy 
for infertility to prevent ovarian hyperstimulation 
syndrome (OHSS) in women with PCOS undergoing in 
vitro fertilization (IVF). 
7. Recommend against the use of insulin sensitizers, such 
as inositols (due to lack of benefit) or 
thiazolidinediones (given safety concerns), for the 
treatment of PCOS.  
8. Suggest against the use of statins for treatment of 
hyperandrogenism and anovulation in PCOS until 
additional studies demonstrate a favorable risk benefit 
ratio. However, guideline suggests statins in women 
with PCOS who meet current indications for statin 
therapy.   
Evidence-based guideline for the assessment and 
management of polycystic ovary syndrome 
recommends43:   
1. Lifestyle intervention as the first line non-pharmacological 
treatment and management for PCOS. Lifestyle management, 
including diet and exercise programs should be used 
throughout the lifespan in women with PCOS to optimise 
health generally and to alleviate PCOS clinical severity 
including infertility. 
 2. Clomiphene citrate as a first-line pharmacological therapy 
to improve fertility outcomes in women with PCOS and 
anovulatory infertility, with no other infertility factors. 
 3. Recommends against the use of aromatase inhibitors e.g., 
Letrozole as the firstline pharmacological therapy in women 
with PCOS who are anovulatory and infertile, with no other 
infertility factors.  
4. Recommends Gonadotrophins as a second-line 
pharmacological therapy in women with PCOS who have 
clomiphene citrate resistance and/or failure, are anovulatory 
and infertile, with no other infertility factors.  
5. Recommends CC + Metformin or Metformin alone (if BMI 
30kg/m2) as the 2nd line pharmacological agents for 
infertility. 
Conclusion  
In view of PCOS encompassing multiple specialities, a holistic 
approach involving general practitioners, endocrinologists, 
gynaecologists and health educators remains the most 
pragmatic approach. Hyperandrogenism and insulin 
resistance appear to be central cause to the pathophysiology 
of the disease, which appears to be multi-factorial and 
polygenic in nature involving multisystem dysfunction, 
namely reproduction, endocrine and metabolic. Though, a 
plethora of treatment options have arrived for PCOS in 
recent years the lifestyle modification including a structured 
meal plan and exercise schedule remains the cornerstone 
and the most effective modality of treatment till date. As a 
general rule all other treatment options are added to this 
depending upon the gravity of the presenting problems.  
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